Micromet, Inc. (MITI)
Recs
negative independent ratings. eps est are being lowered. charts showing a strong downward trend. big insider selling...CFO sold all his positions.
Recs
Pullback Likely on Relatively Weak Stock
Recs
Innovative technology, using antibodies to make the immune system attack cancer cells could be a major breakthrough, plus they have had positive results in clinical trials
Recs
their patented safe antibody platform will change the standard in treatment of cancer. they are going to create a royality system of revenues sold throughout the pharma industry. in 10 years , heres another 10 bagger.
Dr. D
Recs
4.5 and above is strong resistance in the near term.
Recs
MITI has a too high valuation compared to its sales potential. It is also one of the most loss making companies.
Recs
- Forecasted Earnings per Share of $-0.73 per share
- P/E of of -4.82
- Earnings Yield of -20.74 percent
- Growth to P/E Ratio of -0.20
Recs
bad company ready to go down
Recs
Highly Overpriced with nothing but negative returns!
Recs
Listen carefully: This stock will be at $20 on or around December 6th-9th. These dates are the 50th ASH meeting where MITI will present phae II data from its drug MT203. If results are positive, the stock will soar. So far, results have been close to 100% positive. December will be the time of the catalyst. Get in before its too late. Good Luck
Recs
The worst company on earth.
Recs
Hope I'm not too late on this one....
Recs
Recs
I've been in MITI since Dec 07. Potential of BITE is amazing and although MT103 is their lead candidate, they have many BITE platforms in development.
Check out the Science Magazine article that just rocketed the stock into the high 5's (as high as 6.50. Listen to the company CC that was predicated on the Science Magazine article. Check out the Science Advisory Board panel mambers that MITI stood up a a steering committee for their pending products.
7 of 7 patients tested at the highest doses (which are 5 orders of magnitude lower than existing antibody therapies) showed complete or partial remission. Longest treated candidate is still in remission over a year later.
Even though the stock has moved significantly this year, if the additional data which will be released in Dec at ASCO continues to show promise, the stock will continue to move up sharply.
Recs
cancer research should provide valuable results and may end some forms of cancer
Recs
Small German biotech company working on BiTE (Bispecific T Cell Engagers) technology. They published a phase I study on the use of a CD3 and CD19 small partial antibody 'mix'. The NHL patients treated in this study had very very impressive response rates with extremly low doses in this early phase I study. Long term infusions were used are very logical in the context of this relatively small molecule. The clinical side effects are what you would expect and almost hope for to signal immun activation.
Very impressive technology that might solve the BiTE problems with smaller partial antibodies.
Exciting: very very exciting! I'm in big time. Just to bad I haden't heard about them a few months ago. Just hard to follow so many small biotech companies. Hope their stock price goes down a bit so I could get more of this possibly revolutionary company.
This is one of those rare tech companies that changes all the rule or fails quickly if their technology doesn't work. It's a binary proposition with a risk/ reward I find very positive. Time will tell...
Recs
Gar-bage!
Recs
zzlagerhans wise advice.
Recs
Rather strange - I requested this missing ticker for a company that's been publicly traded for years and immediately eight people gave it green thumbs. Do they really know anything about the company or is that some weird CAPS strategy I would never understand? Regardless, I guess I'll be the first red thumb and the first comment. Micromet is a weak baby biotech inexplicably trading at a three year high. Their platform BiTE technology is designed to bring T cells and cancer cells closer together, kind of like a forced marriage. These types of immunotherapy for cancer have been tried over and over again, and usually nothing comes of it. The company is in the phase of breathlessly reporting "positive" results from phase I trials, which basically means their test subjects didn't immediately fall over and die. Perhaps that's why the stock is flying. But phase II and III trials in cancer are long and generally unrewarding, and it's hard to imagine Micromet maintaining its disproprtionate market cap as their cash reserves dwindle and dilution grows imminent.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 19 of 19